CD8A and neoplasm: Immune cells will be activated at early stage with an elevation of anti-tumor cells (e.g., NK cells and CD8 + cells) but soon inhibited at advanced stage (e.g., the transitory activation of CD4 + and CD8 + T cells, from Th1 to Th2, the increase of regulatory T cells (Tregs)) (9, 10).